Introduction {#s1}
============

Administration of high doses of β-agonists, which were originally developed to treat human bronchial diseases and premature birth, could lead to improved weight gain and carcass yield in livestock ([@r001]; [@r013]). Consequently, this approach has long been used to increase livestock productivity. Toxicity studies have demonstrated that long-term administration of clenbuterol, a member of the β-agonist group, might lead to serious adverse effects in the cardiovascular and nervous systems ([@r011]; [@r015]). Several cases of adverse effects in humans have been linked to the consumption of clenbuterol-contaminated meat products ([@r002]). This led to the prohibition of clenbuterol use in over 150 countries, including European countries ([@r005]).

Ractopamine and zilpaterol belong to the same drug class and have effects similar to those of clenbuterol. These compounds are still used in some countries to promote livestock growth. Although ractopamine is prohibited in most European Union (EU) countries ([@r001]), it is still officially permitted in 27 countries worldwide, including the United States and Canada ([@r009]; [@r023]). Likewise, zilpaterol is authorized for use in South Africa, Mexico, the United States, and Canada ([@r006]). Given Korea's high dependence on meat imported from areas that still use ractopamine and zilpaterol, analysis of the three commonly used β-agonists, clenbuterol, ractopamine, and zilpaterol, in meat products is an important tool for evaluating food safety.

Immunoassays ([@r019]; [@r020]), high-performance liquid chromatography (HPLC) ([@r008]; [@r028]), gas chromatography-mass spectrometry (GC-MS) ([@r025]), and liquid chromatography-mass spectrometry (LC-MS) ([@r027]) have been used to analyze β-agonist residues. Recently, liquid chromatography-tandem mass spectrometry (LC/MS/MS) has been commonly used since it can quantitatively and qualitatively analyze a substance based on the unique characteristics of mass and fragment ions created by an electrical current ([@r011]; [@r014]; [@r018]). Previous studies that have simultaneously analyzed clenbuterol, ractopamine, and zilpaterol by LC/MS/MS were limited in scope to samples from the urine, kidney, liver, and feed ([@r001]; [@r021]; [@r026]).

A method that improved upon individual assays was developed in South Korea in 2013, and has been used for the simultaneous determination of clenbuterol and ractopamine ([@r003]; [@r017]). However, this technique does not include measures for analyzing zilpaterol, which has seen increasing use due to its superior growth-enhancing effects.

Policies regarding permission to use zilpaterol vary among countries, and these differences are becoming increasingly problematic. International safety management efforts for zilpaterol are still lacking. In contrast, clenbuterol is prohibited in most countries and is strictly controlled in countries that permit its use. Similarly, the grounds for safety management of ractopamine were established through the adoption of maximum residue limits (MRLs) by the Codex Alimentarius Commission to ensure human health and safety. The limits shown in [Table 1](#t001){ref-type="table"} were based on a risk assessment published by the Joint FAO/WHO Export Committee on Food Additives (JECFA) in July 2012 ([@r007]). Therefore, a method that simultaneously measures all three β-agonists would be beneficial. To that end, a new method that met Codex guidelines and had a high detection efficiency was developed for the simultaneous detection of clenbuterol, ractopamine, and zilpaterol in muscle tissue, the primary source of meat. The method was subsequently validated using a collection of meats and meat byproducts.

###### Comparison of tolerated ractopamine levels among the FDA, Codex, and Health Canada

  Tissue Type   Animal   Tolerated Ractopamine Level (μg/kg)           
  ------------- -------- ------------------------------------- ------- ----
  Muscle        Cattle   10                                    30      10
  Pig           10       50                                    10      
  Turkey        NE^1^    100                                   30      
  Liver         Cattle   40                                    90      40
  Pig           40       150                                   40      
  Turkey        NE       450                                   20      
  Kidney        Cattle   90                                    NT^2^   90
  Pig           90       NT                                    90      
  Turkey        NE       NT                                    NT      

^1^NE, not established; ^2^NT, no tolerance; ^3^Codex, [@r007]; ^4^FDA, [@r023]; ^5^[@r009]

Materials and Methods {#s2}
=====================

Reagents and standards {#s2a}
----------------------

Acetonitrile, *n*-hexane, and ethyl acetate (Burdick & Jackson, USA) were used as extraction solvents. Potassium carbonate (K~2~CO~3~; Merck, Germany), formic acid (Fluka, USA), and anhydrous sodium sulfate (Junsei Chemical, Japan) were used as pretreatment and mobile phase solvents. Triple distilled water was purified through a Milli-Q system (Millipore, USA). Clenbuterol (clenbuterol hydrochloride, 99.8%), ractopamine (ractopamine hydrochloride, 99.8%), and zilpaterol (zilpaterol hydrochloride, 99.8%) (Dr. Ehrenstorfer GmbH, Germany) were used as standards, whereas clenbuterol-d~9~, zilpaterol-d~7~ (Dr. Ehrenstorfer GmbH, Germany), and ractopamine-d~3~ (CDN_ISOTOPES, Canada) were used as internal standards. All standards and internal standards were diluted with methanol (Burdick & Jackson, USA).

For each of the three standards and three internal standards, a 100 mg/kg stock solution was prepared in methanol based on the known purity and molecular weight of each substance. From these stock solutions, working standard solutions of clenbuterol, ractopamine, and zilpaterol at concentrations of 100, 200, and 200 μg/kg, respectively, were prepared by dilution in methanol. The same procedure was followed for clenbuterol-d~9~, ractopamined-d~3~, and zilpaterol-d~7~ to yield solutions of 100, 200, and 200 μg/kg, respectively. Stock and working standard solutions were stored at -20℃ and diluted to individual concentrations by using 0.1% formic acid(v/v), as required.

Sample treatment and extraction {#s2b}
-------------------------------

Frozen chunks of beef, pork, and beef byproducts imported from several countries were used as samples. Prior to analysis, the samples were thawed and then ground using a mixer (HMF-560/HK, Hanil, Korea). Five grams of each homogenized, refrigerated sample was placed into 50 mL centrifuge tubes. The working standard solution of each internal standard (50 μL), 1 mL of 4 M K~2~CO~3~, and 5 mL of distilled water were added to each sample, and the mixture was stirred for 10 min. Ten milliliters of ethyl acetate was then added and the mixture was shaken for 10 min. Next, 10 g of anhydrous sodium sulfate was added and mixed for 10 min to absorb residual water. The solution was centrifuged for 10 min at 4,000 rpm and -4℃, and the supernatant was transferred to a new 50 mL centrifuge tube. Then, 10 mL of ethyl acetate was added to the solution, and the resulting supernatant was isolated using the same extraction procedure. The combined supernatants were gently enriched with nitrogen at 40℃ to obtain a final volume of 2-3 mL. Ten milliliters of acetonitrile and 15 mL of *n*-hexane were added to the concentrate and vortexed for 10 min. The mixture was centrifuged for 10 min at 4,000 rpm and -4℃ to separate the organic layer (acetonitrile). The isolated organic layer was gently enriched with nitrogen at 40℃ and evaporated to dryness. The residue was dissolved in 1 mL of 0.1% formic acid, which served as solvent A for the chromatographic analysis, and 0.5 mL of the solution was filtered through a 0.2 μm polyvinylidenedifluoride syringe filter prior to injection.

Conditions and experimental set-up for chromatography and mass spectrometry {#s2c}
---------------------------------------------------------------------------

LC-MS (API 4000, AB SCIEX, USA) was used to develop a simultaneous determination method for clenbuterol, ractopamine, and zilpaterol. Separation was performed with X Bridge C~18~ (2.1 mm × 150 mm, 3.5 μm; Waters, Ireland), and the column temperature was maintained at 35℃. The analysis was carried out with 0.1% formic acid (solvent A) and acetonitrile (solvent B) as the mobile phase solvents. Initial mobile conditions were set to 90% A and held for 1 min. The fraction of A was linearly decreased to 10% over 7 min and held at 10% for 3 min. At 10.10 min, the compositions were returned to 90% A and held there until 15 min. The flow rate was maintained at 0.4 mL/min, and the injection volume was 10 μL. Positive electrospray ionization mode was selected, and the analysis was performed in multiple reaction monitoring mode. The source temperature was set at 600℃. The precursor ion, product ions, collision energy, and dwell time for each substance are listed in [Table 2](#t002){ref-type="table"}.

###### Mass spectrometry transition conditions and retention times

  Compounds           Transition          Dwell time (s)   Collision Energy (eV)   Retention time (min)
  ------------------- ------------------- ---------------- ----------------------- ----------------------
  Clenbuterol         276.9 to 203.3^1^   0.05             22.68                   5.2
  276.9 to 259.3^2^   0.05                15.33                                    
  Clenbuterol-d~9~    286.2 to 204.2      0.05             23.08                   5.2
  286.2 to 268.2      0.05                15.41                                    
  Ractopamine         302.0 to 164.0^1^   0.05             22.43                   4.8
  302.0 to 107.0^2^   0.05                40.04                                    
  Ractopamine~3~      305.0 to 124.0      0.05             31.00                   4.8
  305.0 to 107.0      0.05                35.00                                    
  Zilpaterol          261.9 to 244.2^1^   0.05             17.00                   1.7
  261.9 to 185.1^2^   0.05                35.00                                    
  Zilpaterol-d~7~     269.1 to 251.3      0.05             19.00                   1.7
  269.1 to 185.2      0.05                35.00                                    

^1^Ion for quantification; ^2^Ion for identification.

MS/MS optimization {#s2d}
------------------

Conventional analysis methods for clenbuterol and ractopamine were used to determine the optimal assay conditions for mass spectrometry. Since ions at m/z 203 and 259 have been used in published literature regarding clenbuterol, the collision energy shown in [Table 2](#t002){ref-type="table"} was applied to the product ion to obtain ions at these m/z ratios ([@r001]; [@r003]; [@r021]). For ractopamine, [@r001] and [@r003] monitored m/z 284 and 164 or m/z 284 and 107 daughter ions, respectively. In this study, m/z 164 and 107 ions were used to track ractopamine because they showed high sensitivity upon application of collision energy, as shown in [Table 2](#t002){ref-type="table"}. To detect zilpaterol, [@r001] used m/z 244 and 202 ions, and [@r021] used m/z 244 and 185 ions. In the present study, ions at m/z 244 and 185, which showed the highest sensitivity upon application of collision energy, were monitored as shown in [Table 2](#t002){ref-type="table"}. While the previous studies used ractopamine-d~5~, cimaterol-d~7~, and clenbuterol-d~9~ as internal standards ([@r001]; [@r016]; [@r021]), zilpaterol-d~7~ was used as an internal standard for zilpaterol to improve efficiency and reproducibility in the present study.

Validation {#s2e}
----------

Linearity, recovery, limit of quantification (LOQ), and reproducibility tests were conducted to validate our method according to the Codex guidelines ([@r004]). Three imported samples each of beef, pork, and beef byproducts were used for these validation experiments. Three different concentrations of each sample were tested. Calibration curves were prepared at concentrations of 0.2-16 μg/kg for clenbuterol and zilpaterol, and 0.5-32 μg/kg for ractopamine, for which MRLs have been established. The correlation coefficient (*R*^2^) for each calibration curve was calculated, and the LOQ with a signal-to-noise ratio greater than 10 was obtained for each substance. Coefficients of variation (CV) were calculated as the ratio of the standard deviation to the mean. [Fig. 1](#f001){ref-type="fig"} shows the chromatogram for each substance after injection at the LOQ level. To evaluate the accuracy and precision of our method, the recovery rate was also determined using concentrations that were 0.5, 1, and 2 times the MRLs (0.005, 0.01, and 0.02 mg/kg) for ractopamine, and 1, 2, and 4 times the LOQ values (0.2, 0.4, and 0.8 μg/kg) for clenbuterol and zilpaterol. Peak retention times in the chromatogram were compared and adjusted according to the internal standards to determine recovery rates using the content values of clenbuterol, ractopamine, and zilpaterol. Each concentration was analyzed in triplicate to verify the experimental methods.

![**Ion chromatograms of zilpaterol, clenbuterol, and ractopamine at the limit of quantification (LOQ).** The daughter ion chromatograms for A, zilpaterol; B, clenbuterol;and C, ractopamineare shown for drugs injected into meat samples at the LOQ level (0.2 μg/kg for zilpaterol and clenbuterol and 0.4 μg/kg for ractopamine).](kosfa-35-121-f001){#f001}

Results and Discussion {#s3}
======================

Comparison with current β-agonist detection methods {#s3a}
---------------------------------------------------

A method for the simultaneous determination of clenbuterol and ractopamine was developed in 2013 in South Korea and is currently used as a Food Code analysis method ([@r012]). [Fig. 3](#f003){ref-type="fig"} compares the Food Code analysis and Food Safety and Inspection Service (FSIS) methods with the new method developed herein. The FSIS method comprises eight steps and does not include solid phase extraction and deproteinization steps, as is the case in our method ([@r022]). Notably, there are additional examples of methods that do not use deproteinization steps for the analyses of feed and milk ([@r014]; [@r021]). We used 4 M K~2~CO~3~ to adjust the pH of the solution to strongly basic, and 5 mL of triple distilled water to promote dispersion of the sample in the pretreatment solvent and to increase the recovery rate. We also used acetonitrile and hexane in place of saturated methanol and hexane to increase the liquid-liquid distribution effect ([@r011]), and maintained the temperature during nitrogen decompression at 40℃, rather than 55℃, to minimize evaporation ([@r014]; [@r016]). Finally, we used 0.1% aqueous formic acid and acetonitrile as the mobile phase instead of buffered ammonium acetate to ensure no overlapping retention times, encourage optimal peak shape, and minimize run time ([Fig. 2](#f002){ref-type="fig"}).

![**Total chromatograms of standard solutions.** Peaks: zilpaterol (A, B), zilpaterol-d~7~ (C, D), clenbuterol (E, F), clenbuterol-d~9~ (G, H), ractopamine (I, J), ractopamine-d~3~ (K, L).](kosfa-35-121-f002){#f002}

![Comparison of the Food Code analysis, the new analysis method, and an analysis by the United States Food Safety and Inspection Service (FSIS). A, The Food Code method; B, the new analysis method; C, the U.S. FSIS method.](kosfa-35-121-f003){#f003}

Applicability {#s3b}
-------------

In our validation tests, *R*^2^ values for the clenbuterol, ractopamine, and zilpaterol calibration curves were 0.9992, 0.9998, and 0.9979, respectively. The LOQ was 0.2 μg/kg for clenbuterol and zilpaterol, and 0.4 μg/kg for ractopamine. The average recovery rates were 109.1-118.3% for clenbuterol, 95.3-109.0% for ractopamine, and 94.1-120.0% for zilpaterol. The CV values were less than 10.58% for all three compounds. These results met the Codex criteria for linearity, recovery rate, LOQ, CV, and reproducibility ([Table 3](#t003){ref-type="table"}). Accordingly, these findings confirmed the applicability of our method.

###### Validation data for clenbuterol, ractopamine, and zilpaterol in meat samples

  Compounds     *R^2^*^1^   LOQ^2^ (μg/kg)   Peak concentration (mg/kg)   Beef     Pork     Beef byproducts                   
  ------------- ----------- ---------------- ---------------------------- -------- -------- ----------------- ------ -------- ------
  Clenbuterol   0.9992      0.2              0.0002                       113.33   5.09     116.67            4.95   113.33   5.09
  0.0004        118.33      2.44             118.33                       2.44     116.67   4.95                              
  0.0008        112.50      2.22             109.17                       3.50     110.00   2.27                              
  Ractopamine   0.9998      0.4              0.0050                       95.33    9.46     104.00            5.77   102.00   3.40
  0.0100        101.17      8.22             98.83                        2.04     109.00   10.58                             
  0.0200        103.33      2.79             104.17                       6.04     103.33   2.79                              
  Zilpaterol    0.9979      0.2              0.0002                       110.00   0.00     113.33            5.09   120.00   0.00
  0.0004        106.67      2.71             110.00                       9.09     105.00   0.00                              
  0.0008        95.83       3.98             98.83                        3.98     94.17    3.07                              

^1^*R*^2,^ correlation coefficient; ^2^LOQ, limit of quantification; ^3^CV, coefficient of variation.

Data are expressed as the mean value of 3 experiments.

International trends in β-agonist drug permissibility {#s3c}
-----------------------------------------------------

Based on safety concerns, β-agonist drugs are now considered more controversial than any other veterinary drug internationally. Unlike clenbuterol, which is prohibited from use in livestock in most countries, ractopamine is still authorized for use in over 27 countries, including South Korea. The Codex Alimentarius Commission, the United Nations food standards body, established ractopamine MRLs in 2012, proposing residue levels that have no known impact on human health ([@r007]). Unfortunately, not all countries comply with these Codex MRLs. Although all β-agonists are prohibited for use as growth promoters in the EU ([@r005]), the United States permits the use of a level that is 3-5 times higher than the Codex MRLs ([@r023]). The United States uses a separate standard for turkey, for which Codex has not yet established MRLs. Unlike the United States, Canada follows the limits suggested by Codex, although a separate national standard for turkey does exist. Differences also exist between countries with respect to renal residue tolerance; the permissible tolerance is 90 μg/kg according to Codex guidelines and Canadian laws, but no limits have been set in the United States ([Table 1](#t001){ref-type="table"}). In the United States, zilpaterol detection is permitted at concentrations below 12 μg/kg ([@r023]). Similarly, in Canada zilpaterol at concentrations up to 5, 5, and 2 μg/kg is permitted in cow kidney, liver, and muscle, respectively ([@r009]). During the 35th session (2012) of the Codex Alimentarius Commission, JECFA decided to conduct a risk assessment for zilpaterol, and new MRLs for zilpaterol are expected to be established in the near future. Based on trends, it is expected that the new limits maybe controversial and not universally adopted. Consequently, β-agonist use in livestock may remain important, and further studies on human health risk of β-agonists will be necessary. Therefore, our simultaneous determination method of β-agonists in products destined for human consumption may prove timely and beneficial.

Safety issues associated with zilpaterol {#s3d}
----------------------------------------

Despite international trends toward establishing MRLs for zilpaterol, continued controversy surrounding the safety issue of this drug is expected. Although clinical toxicology studies have been conducted in horses ([@r010]; [@r024]), case studies on the toxicity in other animals and humans are still lacking. Since simultaneous analysis of the three β-agonists in livestock food products, the primary source of potential human exposure, has been performed in relatively few studies, it is evident that these issues have not been sufficiently studied at both the domestic and international levels ([@r001]; [@r016]; [@r026]). Herein is reported the validation of a method to simultaneously measure clenbuterol, ractopamine, and zilpaterol in muscle tissue, the primary source of meat.

Application of the new method {#s3e}
-----------------------------

Using our method, we performed residue analysis for levels of the three β-agonists in the following 299 imported meats and byproducts samples: 154 beef, 57 pork, and 88 beef byproducts. Our results revealed that ractopamine was detected in two beef samples, and zilpaterol was detected in one beef and one beef byproduct sample ([Table 4](#t004){ref-type="table"}). Based on these results, we believe that there is non-negligible contamination of imported meat and meat byproducts. In particular, a high detection rate was observed for zilpaterol, for which MRLs have not yet been established, indicating a need for the continued surveillance of this drug. Other less frequently used β-agonists that still pose a health risk, such as cimaterol and salbutamol, could be assessed using similar simultaneous determination method in future studies. In addition, the scope of the method may be extended to include processed meat products.

###### Monitoring data for three β-agonists from 299 samples

  Type          N     Compounds     Samples detected (n)   Residue level (μg/kg)   MRLs^1^ (μg/kg)
  ------------- ----- ------------- ---------------------- ----------------------- -----------------
  Beef          154   Clenbuterol   \-                     \-                      NE^2^
  Ractopamine   2     0.6, 2.0      10                                             
  Zilpaterol    1     0.01          NE                                             
  Pork          57    Clenbuterol   \-                     \-                      NE
  Ractopamine   \-    \-            10                                             
  Zilpaterol    \-    \-            NE                                             
  Beef          88    Clenbuterol   \-                     \-                      NE
  Ractopamine   \-    \-            10                                             
  Zilpaterol    1     6.3           NE                                             

^1^MRLs, maximum residue limits; ^2^NE, not established.

Conclusion {#s4}
==========

A new method for the simultaneous determination of three β-agonists, including zilpaterol, was developed. The pretreatment method was modified to reduce the analysis time while enhancing detection efficiency. Moreover, the validation test results met the international Codex guideline standards, verifying that the method is applicable for actual practice. This method should enable rapid and efficient analysis of β-agonists and was applicable to muscle samples, making it appropriate for further studies of β-agonists in meat. Also, it had the advantage of determining zilpaterol, which is not included in the Food Code method, at lower levels than those detectable using the US FSIS method. Additional analyses of zilpaterol may facilitate continued management of the drug and prove to be useful for assessing the risk and establishing MRLs for zilpaterol in the future. Furthermore, it is hoped that this method could be utilized to manage the safety of imported meat products from countries where zilpaterol use is still permitted, thereby improving public health and preventing β-agonist poisoning due to secondary contamination.
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